The U.S. Food and Drug Administration (FDA) has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with ...

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in ...

2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...